gulp1 Antibody

What is GULP1 and what are its primary cellular functions?

GULP1 is an adaptor protein known to facilitate phagocytosis and plays important roles in multiple cellular processes . Research has established that GULP1:

• Functions as a downstream target of Androgen Receptor (AR) signaling in cancer cells

• Regulates sensitivity to cisplatin treatment in bladder cancer

• Controls Eph/ephrin trogocytosis (the process by which cells exchange membrane fragments and associated proteins)

• Contributes to cell rearrangements during embryonic development

In bladder cancer, GULP1 knockdown results in cisplatin resistance accompanied by decreased apoptosis and altered cell cycle distribution, suggesting a critical role in chemosensitivity mechanisms .

How is GULP1 expression regulated in normal and cancerous tissues?

GULP1 expression is directly regulated by Androgen Receptor (AR) signaling. Chromatin immunoprecipitation assays have demonstrated direct binding of AR to the GULP1 promoter region . This interaction results in the following regulatory patterns:

• Androgen treatment in AR-positive cells considerably reduces GULP1 expression

• AR overexpression in AR-negative cells decreases GULP1 expression

• AR knockdown increases GULP1 expression

In bladder cancer tissues, GULP1 immunoreactivity is detectable in 90% of non-neoplastic urothelial tissues compared to 74% of neoplastic specimens, indicating downregulation during tumorigenesis . Additionally, GULP1 expression is significantly reduced in high-grade (68%) and muscle-invasive (61%) tumors compared to lower-grade (84%) and non-muscle-invasive (83%) tumors .

What methodologies exist for studying GULP1's role in cancer chemoresistance?

Researchers investigating GULP1's role in chemoresistance typically employ multiple complementary approaches:

• Genetic manipulation: Stable knockdown of GULP1 via shRNA expression in bladder cancer cell lines (UMUC3, 647V) followed by cisplatin sensitivity assays

• Cell viability assays: MTT assays comparing cisplatin dose responses between GULP1-knockdown and control cells

• Apoptosis quantification: TUNEL assays measuring apoptotic rates in GULP1-manipulated cells with/without cisplatin treatment

• Cell cycle analysis: Flow cytometry examination of cell cycle distribution following cisplatin treatment in GULP1-knockdown versus control cells

• Rescue experiments: Re-introduction of siRNA-resistant GULP1 constructs to confirm phenotype specificity

These methods have revealed that GULP1 knockdown significantly reduces cisplatin-induced apoptosis and increases G2/M phase population in bladder cancer cells .

How does GULP1 contribute to trogocytosis and what techniques can visualize this process?

GULP1 plays an essential role in Eph/ephrin trogocytosis, a process critical for cell sorting during development. Live imaging studies demonstrate that GULP1:

• Is dynamically recruited to EphB/ephrinB clusters at cell-cell interfaces

• Regulates trogocytosis in both forward and reverse directions

• Functions in cooperation with Tiam2 (a Rac-specific guanine nucleotide exchange factor)

• Recruits the endocytic GTPase dynamin to EphB/ephrinB clusters

Researchers can visualize GULP1's role in trogocytosis using:

• Co-culture assays: Mix cells expressing fluorescently-tagged EphB receptors with cells expressing fluorescently-tagged ephrinB ligands

• Live-cell imaging: Track the formation of Eph/ephrin clusters and subsequent GULP1 recruitment using fluorescently tagged proteins (GFP-GULP1)

• Time-lapse microscopy: Capture the transient enrichment of GULP1 at trogocytosis sites and its dissociation after vesicle internalization

When GULP1 is knocked down, ephrinB1 trans-endocytosis from donor to responder cells is significantly reduced, while GULP1 overexpression enhances this process .

What is the relationship between GULP1 expression and clinical outcomes in cancer patients?

GULP1 expression levels show significant correlations with clinical parameters in bladder cancer patients:

As shown in the table above, moderate/strong GULP1 expression (2+/3+) was observed in 53% of chemotherapy responders compared to only 23% of non-responders, establishing a significant association between GULP1 expression and treatment response (P = 0.044) .

Additionally, GULP1 positivity rates show clinically relevant patterns:

• 90% in non-neoplastic urothelial tissues vs. 74% in neoplastic specimens

• 84% in lower-grade tumors vs. 68% in high-grade tumors

• 83% in non-muscle-invasive tumors vs. 61% in muscle-invasive tumors

These findings suggest GULP1 may serve as a potential biomarker for predicting chemotherapy response in bladder cancer.

What are the optimal conditions for GULP1 immunohistochemistry in tissue samples?

For successful GULP1 immunohistochemistry in tissue microarrays and clinical specimens, researchers should consider the following technical parameters:

• Scoring system: Implement a semi-quantitative approach where 0 represents negative staining, 1+ indicates weak staining, 2+ indicates moderate staining, and 3+ represents strong staining

• Positivity threshold: Samples showing any level of staining (1+, 2+, or 3+) are typically considered GULP1-positive

• Controls: Include non-neoplastic urothelial tissues as positive controls (90% positivity rate) and antibody diluent without primary antibody as negative controls

• Statistical analysis: When correlating with clinical outcomes, consider grouping expression levels (e.g., low 0/1+ vs. high 2+/3+) for statistical power

This approach has successfully demonstrated significant associations between GULP1 expression and clinical parameters including tumor grade, invasiveness, and chemotherapy response .

What challenges may researchers encounter when studying GULP1-protein interactions?

Studying GULP1-protein interactions presents several methodological challenges:

• Context-dependent interactions: The interaction between GULP1 and EphB2 is significantly enhanced during trogocytosis conditions but not when cells are stimulated with preclustered soluble ephrinB1-Fc, suggesting that certain interactions may only be detectable under specific cellular contexts

• Transient associations: Live imaging reveals that GULP1 recruitment to ephrinB1 clusters is transient - enriched during cluster formation but dissociating once vesicles are internalized, requiring precise temporal resolution for detection

• Immunoprecipitation conditions: For successful co-immunoprecipitation of GULP1 with interaction partners (e.g., EphB2), researchers should:

  • Use cell-cell stimulation assays rather than soluble ligand stimulation

  • Compare full-length receptors versus truncated variants lacking cytoplasmic domains

  • Validate interactions using both overexpression systems and endogenous proteins

• Bidirectional processes: When studying trogocytosis, researchers must account for bidirectional vesicle exchange, potentially requiring dual fluorescent labeling approaches to distinguish forward and reverse processes

How should researchers design GULP1 knockdown/overexpression experiments?

When manipulating GULP1 expression levels, researchers should implement the following experimental design elements:

• Knockdown validation: Confirm reduced GULP1 protein levels via Western blot analysis following siRNA treatment

• Rescue controls: Include conditions with siRNA-resistant GULP1 expression to validate phenotype specificity

• Baseline vs. stimulated conditions: Note that GULP1 knockdown may not affect baseline cellular processes (proliferation, apoptosis, migration, invasion) but significantly impacts responses to stimuli such as cisplatin treatment

• Cell type selection: Consider that different cell types show varying baseline GULP1 expression levels (higher in AR-negative cells than AR-positive cells)

• Complementary gain-of-function studies: Complement knockdown approaches with overexpression studies, as GULP1 overexpression can enhance processes like ephrinB1 trans-endocytosis

• Quantitative phenotypic assays: Implement appropriate quantitative assays for each cellular process, such as:

  • MTT assay for proliferation

  • TUNEL assay for apoptosis

  • Flow cytometry for cell cycle analysis

  • Wound-healing assay for migration

  • Transwell invasion assay for invasion

How can researchers distinguish between GULP1-dependent and independent cellular processes?

To differentiate GULP1-dependent from GULP1-independent processes, researchers should employ these methodological approaches:

• Comparative knockdown phenotyping: Systematically assess multiple cellular processes (proliferation, apoptosis, migration, invasion) in GULP1-knockdown versus control cells to identify GULP1-dependent functions

• Stimulus-specific responses: Test responses to specific stimuli (cisplatin, cell-cell contact), as GULP1 functions may only be revealed under certain conditions

• Pathway analysis: Investigate potential downstream mediators of GULP1 function, such as SMAD3 activation or inactivation of AKT/PDK1 and MAPK pathways

• Protein domain analysis: Express GULP1 mutants lacking specific functional domains to determine which domains are required for particular cellular processes

• Temporal resolution: Use time-lapse microscopy to track the dynamic recruitment of GULP1 to cellular structures during processes like trogocytosis, establishing temporal relationships with other molecular events

How might GULP1 function as a potential therapeutic target or biomarker?

Based on current research findings, GULP1 shows promise as both a biomarker and potential therapeutic target:

As a biomarker:

• GULP1 expression levels in muscle-invasive bladder cancer correlate significantly with response to cisplatin-based chemotherapy

• Low GULP1 expression (0/1+) is significantly associated with chemoresistance (P = 0.044)

• GULP1 expression is progressively downregulated during bladder cancer progression (from non-neoplastic tissue to high-grade, muscle-invasive tumors)

As a therapeutic target:

• Enhancing GULP1 expression or activity might potentially sensitize resistant tumors to cisplatin treatment

• Understanding GULP1's role in trogocytosis could provide insights for manipulating cell-cell interactions during development or disease

• The relationship between AR signaling and GULP1 suggests potential combination strategies involving AR pathway inhibitors and chemotherapy

Future research should focus on developing methods to modulate GULP1 expression or activity in vivo and evaluating whether such modulation can enhance chemotherapy efficacy in resistant tumors.

What are the unresolved questions regarding GULP1's molecular mechanisms?

Despite significant progress, several aspects of GULP1 function remain to be elucidated:

• Complete signaling network: While GULP1 has been linked to SMAD3 activation and inactivation of AKT/PDK1 and MAPK pathways, the complete signaling network downstream of GULP1 remains incompletely characterized

• Structural determinants: The specific protein domains and structural features of GULP1 that mediate its various interactions (with EphB2, dynamin, Tiam2) need further clarification

• Cell-type specificity: Why GULP1 knockdown affects cisplatin sensitivity in some cell types but not proliferation/migration/invasion in others requires investigation

• Mechanistic connection to AR: While AR directly regulates GULP1 expression, how this regulation interfaces with other AR-dependent processes in cancer progression is unclear

• Trogocytosis specificity: How GULP1 specifically facilitates Eph/ephrin trogocytosis versus other forms of trogocytosis requires further study

Addressing these questions will require integrated approaches combining structural biology, signaling pathway analysis, and in vivo models.